[Remote] Senior Director, Quality Control Analytical Sciences at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Drug DevelopmentIndustries

Skills

Key technologies and capabilities for this role

Quality ControlAnalytical SciencesMethod QualificationMethod ValidationMethod TransferDrug SubstanceDrug ProductStability TestingSpecification JustificationShelf-life ManagementCMC Regulatory StrategyBiologicsAntibody Engineering

Questions & Answers

Common questions about this position

What qualifications are required for the Senior Director, Quality Control Analytical Sciences role?

A PhD in a relevant discipline such as analytical biochemistry or related field is required, along with 15+ years of QC experience with complex biologics, particularly monoclonal antibodies, spanning late-stage development and commercialization.

What leadership qualities does the ideal candidate have?

The ideal candidate is a proven people leader with a growth mindset, willing to learn from others, and dedicated to promoting a psychologically safe environment.

What is the company culture like at Apogee Therapeutics?

Apogee Therapeutics is a fast-paced company committed to building an exceptional company culture founded on C.O.R.E. values: Caring, Original, Resilient, and Egoless, offering opportunities to shape the culture and grow professionally.

What is the reporting structure for this position?

The role reports to the VP of Analytical Development and Quality Control.

What makes a strong candidate for this Senior Director role?

A strong candidate has a PhD, 15+ years of QC experience with biologics like monoclonal antibodies in late-stage development, proven leadership skills with a growth mindset, and excellent communication abilities.

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free